AIM ImmunoTech Inc.
AIM ImmunoTech Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88,000.00, down 48.2% from fiscal 2024. In the quarter to June 2026, revenue grew 4.00%, EPS grew 94.0% and free cash flow fell 167.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow AIM
AIM ImmunoTech Inc. (AIM) Piotroski F-score
AIM ImmunoTech Inc.'s Piotroski F-score for fiscal 2025 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, down from 4 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 3 | (1.00) |
| FY2024 | 4 | 1.00 |
| FY2023 | 3 | 0.00 |
| FY2022 | 3 | (1.00) |
| FY2021 | 4 | (1.00) |
| FY2020 | 5 | 2.00 |
| FY2019 | 3 | 2.00 |
| FY2018 | 1 | (2.00) |
| FY2017 | 3 | 0.00 |
| FY2016 | 3 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (194.00%) | (123.76%) | Fail | 0 |
| Positive operating cash flow | (10.96m) | (14.89m) | Fail | 0 |
| Rising return on assets | (194.00%) | (123.76%) | Fail | 0 |
| Cash flow above net income | 3.00m | 2.43m | Pass | 1 |
| Falling long-term leverage | 0.13 | 0.00 | Fail | 0 |
| Rising current ratio | 0.53 | 0.44 | Pass | 1 |
| No new shares issued | 1,618,600 | 560,200 | Fail | 0 |
| Rising gross margin | (45.45%) | 81.76% | Fail | 0 |
| Rising asset turnover | 0.01 | 0.01 | Pass | 1 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR compare | 4 |
| AIM AIM ImmunoTech Inc. | 3 |
| SYBX Synlogic, Inc. compare | 3 |
| NIKI Niki BioSolutions, Inc. compare | 2 |
| TCRT Alaunos Therapeutics, Inc. compare | 2 |
| BCLI Brainstorm Cell Therapeutics Inc. compare | — |
| FBLG FibroBiologics Inc. compare | — |
| SKYE Skye Bioscience, Inc. compare | — |
| ACXP Acurx Pharmaceuticals, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover